<DOC>
	<DOCNO>NCT01826019</DOCNO>
	<brief_summary>The overall objective HOPE-4 Phases ( HT CVD ) develop , implement evaluate evidence-based , contextually appropriate programme cardiovascular disease ( CVD ) risk assessment , treatment control involve : ( 1 ) simplify algorithms implement non-physician health worker ( NPHW ) support e-health technology ( tablet program decision counsel support software ) ; ( 2 ) initiation evidence-based cardiovascular ( CV ) medication ( 3 ) treatment supporter optimize long-term medication lifestyle adherence .</brief_summary>
	<brief_title>Heart Outcomes Prevention Evaluation 4</brief_title>
	<detailed_description>Study design : open-label , parallel cluster randomize controlled trial design . HT Phase : least 50 urban rural community Canada , Colombia Malaysia randomize participate intensive CV risk detection control program NPHW care usual 12 month . CVD Phase : Continuation expansion HT Phase include least 190 urban rural community country within Asia , South America , Sub-Saharan Africa , Canada allocate participate intensive CV risk detection control programme support NPHWs care usual 6 year . Communities randomize 1:1 central randomization system either ) intervention b ) control , screen community complete .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Individuals ( ≥ 50 year ) least ONE follow criterion : 1 . SBP ≥160 mmHg one visit 2 . SBP 140159 mmHg one visit AND participantreported medical diagnosis hypertension 3 . SBP 140159 mmHg one visit AND participant take antiHT medication 4 . SBP ≥130 mmHg one visit AND participantreported medical diagnosis diabetes 5 . SBP ≥130 mmHg one visit AND participant take medication diabetes 6 . Participants meet criterion 15 AND SBP 140159 mmHg one visit AND SBP ≥140 mmHg second visit ≥24 hour apart 1 . Refusal Consent 2 . Actively involved study heart health program would compromise protocol HOPE4 3 . Severe comorbid condition life expectancy &lt; 1 year 4 . Other serious condition ( ) logistic factor likely interfere study participation ability complete trial , appropriate country region .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>